Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with Cystic Fibrosis~* Must have the G551D-CFTR mutation on at least 1 allele~* FEV1 ≥40% of predicted normal for age, gender, and height at Screening~* 12 years of age or older~* Must be able to swallow tablets~Exclusion Criteria:~* History of solid organ or hematological transplantation~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within the 30 days prior to screening~* Use of inhaled hypertonic saline treatment within 14 days prior to the Screening Visit~* Extensive body tattoos or other physical features that will confound MRI

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VX-770 (Type: EXPERIMENTAL): Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).